Company intelligence / Profile preview

Jingrui Therapeutics

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jingrui Pharmaceutical focuses on developing innovative anti-cancer drugs using small molecules, protein degraders, and biologics targeting key cancer-related proteins. The company is led by experienced scientists from global pharmaceutical companies and aims to deliver breakthrough therapies for oncology patients. Its pipeline includes targeted therapies against kinases, phosphatases, oncoproteins, and transcription factors. Expansion into other therapeutic areas is planned for the future[2][3].

Therapeutic areas: Oncology
Modalities: Small molecule inhibitorsProtein degradersLarge biological interventions[2]
Industry: Biotech

Drug pipeline

1 asset

JRD-018

IND

Indications: Advanced solid tumors, Hematologic malignancies, Brain metastases, Primary brain tumors

Beyond the preview

Go deeper on Jingrui Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jingrui Therapeutics.

Explore the full profile